@article {1538345,
	title = {Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis},
	journal = {Am J Ophthalmol},
	volume = {223},
	year = {2021},
	month = {2021 Mar},
	pages = {75-82},
	abstract = {PURPOSE: To report a case series of patients with treatment-resistant Acanthamoeba keratitis (AK) using oral miltefosine, often as salvage therapy. DESIGN: Descriptive, retrospective multicenter case series. METHODS: We reviewed 15 patients with AK unresponsive to therapy who were subsequently given adjuvant systemic miltefosine between 2011 and 2017. The main outcome measures were resolution of infection, final visual acuity, tolerance of miltefosine, and clinical course of disease. RESULTS: All patients were treated with biguanides and/or diamidines or azoles without resolution of disease before starting miltefosine. Eleven of 15 patients retained count fingers or better vision, and all were considered disease free at last follow-up. Eleven of 15 patients had worsening inflammation with miltefosine, with 10 of them improving with steroids. Six patients received multiple courses of miltefosine. Most tolerated oral miltefosine well, with mild gastrointestinal symptoms as the most common systemic side effect. CONCLUSIONS: Oral miltefosine is a generally well-tolerated treatment adjuvant in patients with refractory AK. The clinician should be prepared for a steroid-responsive inflammatory response frequently encountered during the treatment course.},
	issn = {1879-1891},
	doi = {10.1016/j.ajo.2020.09.048},
	author = {Thulasi, Praneetha and Saeed, Hajirah N and Rapuano, Christopher J and Hou, Joshua H and Appenheimer, Alpheus B and Chodosh, James and Kang, Joann J and Morrill, Amber M and Vyas, Neil and Zegans, Michael E and Zuckerman, Richard and Tu, Elmer Y}
}
